Dexamethasone intravitreal implant downregulates PDGFR-α and upregulates caveolin-1 in experimental branch retinal vein occlusion

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Dexamethasone intravitreal implant downregulates PDGFR-α and upregulates caveolin-1 in experimental branch retinal vein occlusion. / Cehofski, Lasse Jørgensen; Kruse, Anders; Magnusdottir, Sigriður Olga; Alsing, Alexander Nørgård; Nielsen, Jonas Ellegaard; Kirkeby, Svend; Honoré, Bent; Vorum, Henrik.

In: Experimental Eye Research, Vol. 171, 06.2018, p. 174-182.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Cehofski, LJ, Kruse, A, Magnusdottir, SO, Alsing, AN, Nielsen, JE, Kirkeby, S, Honoré, B & Vorum, H 2018, 'Dexamethasone intravitreal implant downregulates PDGFR-α and upregulates caveolin-1 in experimental branch retinal vein occlusion', Experimental Eye Research, vol. 171, pp. 174-182. https://doi.org/10.1016/j.exer.2018.02.029

APA

Cehofski, L. J., Kruse, A., Magnusdottir, S. O., Alsing, A. N., Nielsen, J. E., Kirkeby, S., Honoré, B., & Vorum, H. (2018). Dexamethasone intravitreal implant downregulates PDGFR-α and upregulates caveolin-1 in experimental branch retinal vein occlusion. Experimental Eye Research, 171, 174-182. https://doi.org/10.1016/j.exer.2018.02.029

Vancouver

Cehofski LJ, Kruse A, Magnusdottir SO, Alsing AN, Nielsen JE, Kirkeby S et al. Dexamethasone intravitreal implant downregulates PDGFR-α and upregulates caveolin-1 in experimental branch retinal vein occlusion. Experimental Eye Research. 2018 Jun;171:174-182. https://doi.org/10.1016/j.exer.2018.02.029

Author

Cehofski, Lasse Jørgensen ; Kruse, Anders ; Magnusdottir, Sigriður Olga ; Alsing, Alexander Nørgård ; Nielsen, Jonas Ellegaard ; Kirkeby, Svend ; Honoré, Bent ; Vorum, Henrik. / Dexamethasone intravitreal implant downregulates PDGFR-α and upregulates caveolin-1 in experimental branch retinal vein occlusion. In: Experimental Eye Research. 2018 ; Vol. 171. pp. 174-182.

Bibtex

@article{eb480ac51dc14e82b3a844d53e71042d,

title = "Dexamethasone intravitreal implant downregulates PDGFR-α and upregulates caveolin-1 in experimental branch retinal vein occlusion",

abstract = "A dexamethasone (DEX) intravitreal implant (OZURDEX) provides an effective treatment of inflammation secondary to branch retinal vein occlusion (BRVO). Retinal proteome changes which mediate the beneficial effects of the implant remain poorly understood. To study retinal proteome changes in BRVO following an intervention with a DEX implant this study combined an experimental model of BRVO with proteomic techniques. In eight Danish Landrace pigs experimental BRVO was induced in both eyes using argon laser. After inducing BRVO a DEX implant was injected into the right eye of each animal while the left control eye was given an identical injection without an implant. Fifteen days after BRVO and DEX implant intervention the retinas were excised and analyzed with tandem mass tag based mass spectrometry. A total of 26 significantly changed proteins were identified. DEX intervention reduced the retinal levels of platelet-derived growth factor receptor-α (PDGFR-α) and vascular endothelial growth factor receptor 2 (VEGFR-2). DEX treatment resulted in increased levels of caveolin-1, peptidyl-prolyl cis-trans isomerase FKBP5 and transgelin. Changes in PDGFR-α and caveolin-1 were confirmed with immunohistochemistry. In BRVO treated with the DEX implant a strong reaction for caveolin-1 was observed in the innermost retinal layers. DEX implant intervention may inhibit PDGF signaling by decreasing the retinal level of PDGFR-α while an increased content of caveolin-1 may help maintain the integrity of the blood-retinal barrier.",

author = "Cehofski, {Lasse J{\o}rgensen} and Anders Kruse and Magnusdottir, {Sigri{\dh}ur Olga} and Alsing, {Alexander N{\o}rg{\aa}rd} and Nielsen, {Jonas Ellegaard} and Svend Kirkeby and Bent Honor{\'e} and Henrik Vorum",

year = "2018",

month = jun,

doi = "10.1016/j.exer.2018.02.029",

language = "English",

volume = "171",

pages = "174--182",

journal = "Experimental Eye Research",

issn = "0014-4835",

publisher = "Academic Press",

}

RIS

TY - JOUR

T1 - Dexamethasone intravitreal implant downregulates PDGFR-α and upregulates caveolin-1 in experimental branch retinal vein occlusion

AU - Cehofski, Lasse Jørgensen

AU - Kruse, Anders

AU - Magnusdottir, Sigriður Olga

AU - Alsing, Alexander Nørgård

AU - Nielsen, Jonas Ellegaard

AU - Kirkeby, Svend

AU - Honoré, Bent

AU - Vorum, Henrik

PY - 2018/6

Y1 - 2018/6

N2 - A dexamethasone (DEX) intravitreal implant (OZURDEX) provides an effective treatment of inflammation secondary to branch retinal vein occlusion (BRVO). Retinal proteome changes which mediate the beneficial effects of the implant remain poorly understood. To study retinal proteome changes in BRVO following an intervention with a DEX implant this study combined an experimental model of BRVO with proteomic techniques. In eight Danish Landrace pigs experimental BRVO was induced in both eyes using argon laser. After inducing BRVO a DEX implant was injected into the right eye of each animal while the left control eye was given an identical injection without an implant. Fifteen days after BRVO and DEX implant intervention the retinas were excised and analyzed with tandem mass tag based mass spectrometry. A total of 26 significantly changed proteins were identified. DEX intervention reduced the retinal levels of platelet-derived growth factor receptor-α (PDGFR-α) and vascular endothelial growth factor receptor 2 (VEGFR-2). DEX treatment resulted in increased levels of caveolin-1, peptidyl-prolyl cis-trans isomerase FKBP5 and transgelin. Changes in PDGFR-α and caveolin-1 were confirmed with immunohistochemistry. In BRVO treated with the DEX implant a strong reaction for caveolin-1 was observed in the innermost retinal layers. DEX implant intervention may inhibit PDGF signaling by decreasing the retinal level of PDGFR-α while an increased content of caveolin-1 may help maintain the integrity of the blood-retinal barrier.

AB - A dexamethasone (DEX) intravitreal implant (OZURDEX) provides an effective treatment of inflammation secondary to branch retinal vein occlusion (BRVO). Retinal proteome changes which mediate the beneficial effects of the implant remain poorly understood. To study retinal proteome changes in BRVO following an intervention with a DEX implant this study combined an experimental model of BRVO with proteomic techniques. In eight Danish Landrace pigs experimental BRVO was induced in both eyes using argon laser. After inducing BRVO a DEX implant was injected into the right eye of each animal while the left control eye was given an identical injection without an implant. Fifteen days after BRVO and DEX implant intervention the retinas were excised and analyzed with tandem mass tag based mass spectrometry. A total of 26 significantly changed proteins were identified. DEX intervention reduced the retinal levels of platelet-derived growth factor receptor-α (PDGFR-α) and vascular endothelial growth factor receptor 2 (VEGFR-2). DEX treatment resulted in increased levels of caveolin-1, peptidyl-prolyl cis-trans isomerase FKBP5 and transgelin. Changes in PDGFR-α and caveolin-1 were confirmed with immunohistochemistry. In BRVO treated with the DEX implant a strong reaction for caveolin-1 was observed in the innermost retinal layers. DEX implant intervention may inhibit PDGF signaling by decreasing the retinal level of PDGFR-α while an increased content of caveolin-1 may help maintain the integrity of the blood-retinal barrier.

U2 - 10.1016/j.exer.2018.02.029

DO - 10.1016/j.exer.2018.02.029

M3 - Journal article

C2 - 29505751

VL - 171

SP - 174

EP - 182

JO - Experimental Eye Research

JF - Experimental Eye Research

SN - 0014-4835

ER -

ID: 198227424

Department of Odontology